BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19372254)

  • 1. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
    Barbui T; Carobbio A; Rambaldi A; Finazzi G
    Blood; 2009 Jul; 114(4):759-63. PubMed ID: 19372254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
    Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
    Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Am J Hematol; 2010 Feb; 85(2):97-100. PubMed ID: 20052743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
    Chou YS; Gau JP; Yu YB; Pai JT; Hsiao LT; Liu JH; Hong YC; Liu CY; Yang CF; Chen PM; Chiou TJ; Tzeng CH
    Eur J Haematol; 2013 Mar; 90(3):228-36. PubMed ID: 23281576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
    Caramazza D; Caracciolo C; Barone R; Malato A; Saccullo G; Cigna V; Berretta S; Schinocca L; Quintini G; Abbadessa V; Di Raimondo F; Siragusa S
    Ann Hematol; 2009 Oct; 88(10):967-71. PubMed ID: 19214510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocytosis and risk stratification assessment in essential thrombocythemia.
    Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
    J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC; Gómez M
    Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
    Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia.
    Farrukh F; Guglielmelli P; Loscocco GG; Pardanani A; Hanson CA; De Stefano V; Barbui T; Gangat N; Vannucchi AM; Tefferi A
    Am J Hematol; 2022 Feb; 97(2):E35-E37. PubMed ID: 34822188
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera.
    Krečak I; Holik H; Martina MP; Zekanović I; Coha B; Gverić-Krečak V
    Int J Hematol; 2020 Sep; 112(3):377-384. PubMed ID: 32514928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute coronary disease in essential thrombocythemia and polycythemia vera.
    Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
    J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.
    Palandri F; Polverelli N; Catani L; Ottaviani E; Baccarani M; Vianelli N
    Ann Hematol; 2011 Aug; 90(8):933-8. PubMed ID: 21287350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.
    Pósfai É; Marton I; Borbényi Z; Nemes A
    Anatol J Cardiol; 2016 Jun; 16(6):397-402. PubMed ID: 27182615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
    Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
    Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
    Vannucchi AM; Antonioli E; Guglielmelli P; Rambaldi A; Barosi G; Marchioli R; Marfisi RM; Finazzi G; Guerini V; Fabris F; Randi ML; De Stefano V; Caberlon S; Tafuri A; Ruggeri M; Specchia G; Liso V; Rossi E; Pogliani E; Gugliotta L; Bosi A; Barbui T
    Blood; 2007 Aug; 110(3):840-6. PubMed ID: 17379742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
    Vannucchi AM
    Intern Emerg Med; 2010 Jun; 5(3):177-84. PubMed ID: 19789961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.
    Landolfi R; Di Gennaro L; Barbui T; De Stefano V; Finazzi G; Marfisi R; Tognoni G; Marchioli R;
    Blood; 2007 Mar; 109(6):2446-52. PubMed ID: 17105814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.